Study of ONO-1101 in Patients Scheduled for Coronary Angiography

Ono Pharmaceuticals

Status and phase: Completed; Phase 2

Conditions: Coronary Artery Disease

Treatments: Drug: ONO-1101

Study type: Interventional

Funder types: Industry

Identifiers

NCT00560209

ONO-1101-26

Details and patient eligibility

About

The purpose of this study is to evaluate the efficacy and safety of ONO-1101 in patients scheduled for coronary angiography, in a double-blind, randomized, placebo-controlled, parallel group, multi-center study.

Enrollment: 183 patients

Sex: All

Ages: 20+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• 20 years of age or older
• Heart rate less than 90 beats/min and more than 70 beats/min at entering the CT room

Exclusion criteria

• Previous allergic reactions to contrast agent
• Renal failure
• Asthma
• Concomitant beta-receptor blocking agent

Trial design

Primary purpose: Diagnostic

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: Double Blind

---

183 participants in 3 patient groups, including a placebo group

P

Placebo Comparator group

Treatment:

Drug: ONO-1101

Drug: ONO-1101

Drug: ONO-1101

E2

Experimental group

Treatment:

Drug: ONO-1101

Drug: ONO-1101

Drug: ONO-1101

E1

Experimental group

Treatment:

Drug: ONO-1101

Drug: ONO-1101

Drug: ONO-1101